KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Accured Expenses (2016 - 2022)

Biocryst Pharmaceuticals filings provide 13 years of Change in Accured Expenses readings, the most recent being -$6.3 million for Q4 2022.

  • On a quarterly basis, Change in Accured Expenses fell 2334.15% to -$6.3 million in Q4 2022 year-over-year; TTM through Sep 2022 was $6.6 million, a 6.06% increase, with the full-year FY2021 number at $4.2 million, down 38.4% from a year prior.
  • Change in Accured Expenses hit -$6.3 million in Q4 2022 for Biocryst Pharmaceuticals, down from $6.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.3 million in Q3 2022 to a low of -$6.3 million in Q4 2022.
  • Median Change in Accured Expenses over the past 5 years was $1.4 million (2018), compared with a mean of $763500.0.
  • The widest YoY moves for Change in Accured Expenses: up 1782.79% in 2022, down 2334.15% in 2022.
  • Biocryst Pharmaceuticals' Change in Accured Expenses stood at $1.4 million in 2018, then grew by 4.22% to $1.5 million in 2019, then skyrocketed by 59.76% to $2.4 million in 2020, then tumbled by 88.0% to $284000.0 in 2021, then plummeted by 2334.15% to -$6.3 million in 2022.
  • The last three reported values for Change in Accured Expenses were -$6.3 million (Q4 2022), $6.3 million (Q3 2022), and $284000.0 (Q4 2021) per Business Quant data.